Highlights

• Ion Exchange (India) Limited secured water and wastewater treatment contracts worth approximately ₹205 crore for solar projects.
• Zydus Lifesciences’ US subsidiary received FDA acceptance for its NDA resubmission for a pediatric rare disease therapy.
• Texmaco Rail & Engineering Limited received a domestic order valued at ₹132 crore for supply of railway wagons.

Several listed companies from the Indian stock market reported significant business and regulatory developments, drawing investor attention. Ion Exchange (India) Limited announced major project awards linked to solar manufacturing infrastructure, Zydus Lifesciences received an update from the US FDA regarding its rare disease therapy, and Texmaco Rail & Engineering Limited disclosed a fresh domestic order for freight wagons.

Ion Exchange Bags ₹205 Crore Solar Water Treatment Orders

Ion Exchange (India) Limited (NSE:IONEXCHANG) informed stock exchanges that it has been awarded contracts aggregating to approximately ₹205 crore for Ultra-Pure Water systems, Effluent Treatment Plants (ETP), and Zero Liquid Discharge (ZLD) facilities.

The first contract, valued at around ₹95 crore, was awarded by Rayzon Energy Private Limited. The scope includes process and utility water systems for Rayzon Energy’s 5.1 GW photovoltaic solar project located at Kathwada Village, Surat, Gujarat. The project involves ultra-pure water generation along with wastewater treatment and ZLD systems.

The second contract, amounting to approximately ₹110 crore, was awarded by INOX Solar Limited. This order covers ultra-pure water generation, wastewater treatment systems, and ZLD facilities for INOX Solar’s 5.1 GW solar project at the same location in Surat, Gujarat. Additionally, Ion Exchange will undertake engineering, procurement, and construction activities for a solar cell manufacturing facility in Odisha.

The projects are scheduled for execution within 9 months and 10 months respectively from the date of award.

Zydus Lifesciences Gets FDA Acceptance for NDA Resubmission

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) announced that Sentynl Therapeutics, Inc., its wholly-owned US subsidiary, has received acceptance from the US Food and Drug Administration (FDA) for the resubmission of its New Drug Application (NDA) for copper histidinate (CUTX-101).

The NDA has been accepted as a Class I response, with the FDA assigning January 14, 2026, as the new Prescription Drug User Fee Act (PDUFA) action date. The resubmission followed a Complete Response Letter issued on September 30, 2025, which cited observations related to manufacturing site cGMP compliance. No concerns were raised regarding efficacy or safety data.

CUTX-101 is intended for the treatment of Menkes disease, a rare pediatric genetic disorder. If approved, it would be the first FDA-approved therapy for this condition.

Texmaco Rail Secures ₹132 Crore Wagon Supply Order

Texmaco Rail & Engineering Limited (NSE:TEXRAIL) disclosed that it has received a domestic order from Touax Texmaco Railcar Leasing Private Limited.

The order involves the supply of a rake of BLSS wagons, comprising BLSS and BVCM wagons. The total order value stands at ₹132 crore, excluding taxes. Execution of the contract will take place in tranches, with completion scheduled by July 2026.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.